Divalproex Sodiumdelayed-release
Product Images NDC 33261-621

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodiumdelayed-release (NDC 33261-621). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula Of Divalproex Sodium Delayed Release Tablets. (Divalproex Sod Dr 500mg Tab For Qualitest 1)

Chemical structure diagram of the active ingredient in Divalproex Sodium Delayed-Release. The structure shows the molecular arrangement including carbon chains, carboxyl groups, and sodium ion representation within parentheses indicating polymerization (repeating units).*

FDA Label Image

Figure 1. Percentage Of Patients Achieving ≥ 30% Reduction In Symptom Score From Baseline (Divalproex Sod Dr 500mg Tab For Qualitest 2)

A bar chart titled 'Percentage of Patients Achieving ≥ 30% Reduction in Symptom Score From Baseline' comparing placebo (PBO) and divalproex sodium (DVPX) in two studies. Study 1 (YMRS) shows 26% for placebo and 60% for divalproex sodium. Study 2 (MRS) shows 29% for placebo and 58% for divalproex sodium. The chart includes a note indicating statistical significance (p < 0.05) and defines abbreviations for placebo and divalproex sodium.*

FDA Label Image

Figure 2 (Divalproex Sod Dr 500mg Tab For Qualitest 3)

Figure 2 is a cumulative distribution plot showing the percent reduction in CPS rate for patients treated with Divalproex Sodium compared to placebo. The y-axis represents the percent reduction in CPS rate from -100% to 100%, indicating worsening to improvement, while the x-axis shows the percentage of patients from 100% to 0%. Two lines compare treatment effects: a solid line for Divalproex Sodium and a dashed line for placebo.*

FDA Label Image

Figure 3 (Divalproex Sod Dr 500mg Tab For Qualitest 4)

A line graph titled Figure 3 illustrating the percentage reduction in CPS rate versus the percentage of patients. Two lines compare High Dose (solid line) and Low Dose (dashed line) groups. The vertical axis ranges from -100% to 100%, with 'Improvement' above and 'Worsening' below a midpoint labeled 'No Change.' The horizontal axis shows patient percentages from 100 on the left to 0 on the right.*

FDA Label Image

Figure 4. Mean 4-week Migraine Rates (Divalproex Sod Dr 500mg Tab For Qualitest 5)

A bar chart titled 'Figure 4. Mean 4-week Migraine Rates' comparing migraine rates for Placebo and Divalproex Sodium across two studies. The vertical axis ranges from 0 to 6 migraines. Study 1 shows higher rates for Placebo than Divalproex Sodium; Study 2 shows a similar pattern with higher rates for Placebo. Footnotes note dosages for Divalproex Sodium in each study.*

FDA Label Image

Image Label (Divalproex Sod Dr 500mg Tab For Qualitest 6)

Label for Divalproex Sodium Delayed-Release tablets, 500 mg strength, containing 60 tablets. The label indicates the active ingredient as valproic acid delayed release 500 mg per tablet. It is generic for Depakote and manufactured for Qualitest Pharmaceuticals. The labeler is Aidarex Pharmaceuticals LLC, with NDC 33261-0621-60.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.